Anti-αLβ2 antibodies reveal novel endocytotic cross-modulatory functionality

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• Therapeutic antibodies targeting cell surface receptors offer selective treatments for cancer and immune disorders.
• Generally, antibody effects align with their target interactions, but efalizumab, an anti-integrin αLβ2 antibody, shows broader effects.
• The mechanisms behind efalizumab's extensive biological impact remain unclear.

Purpose of the Study:

• To investigate the mechanisms behind the broad effects of anti-integrin αLβ2 antibodies.
• To compare the effects of anti-αLβ2 antibodies with Fab fragments and small-molecule inhibitors on integrin expression.

Main Methods:

• Primary human lymphocytes were used for in vitro studies.
• Investigated the effects of anti-αLβ2 antibodies, Fab fragments, and small-molecule inhibitors on αLβ2 and α4 integrin expression.

Main Results:

• Anti-αLβ2 monoclonal antibodies (mAbs) directly induce the internalization of α4 integrins.
• This endocytotic effect is specific to the antibody format and not observed with Fab fragments or small-molecule inhibitors.
• The cross-modulation is unidirectional, independent of αLβ2 activation or Fc-mediated crosslinking, and not seen with natalizumab.

Conclusions:

• Identified endocytotic cross-modulation as a novel, non-canonical function of anti-αLβ2 antibodies.
• This phenomenon can significantly alter an antibody's benefit-risk profile, as seen with efalizumab.
• This finding is relevant for other therapeutic antibodies targeting cluster-forming receptors and warrants consideration in pharmacological investigations.